Answer
Erythema multiforme, exfoliative dermatitis and Stevens-Johnson syndrome, some fatal, have been reported in patients receiving parecoxib through post-marketing surveillance.
Sources for this answer
- Parecoxib Seacross 40 mg powder for solution for injectionSeacross Pharmaceuticals Ltd · emc · SmPC §4.4 Special warnings and precautions for use · Version 1Document updated
Sources checked